Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses
NCT07631598
This study is recruiting at 8 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce opioid cravings and withdrawal symptoms. The study compares two ways of connecting people to treatment: Referral to a community treatment provider (usual care before the new program begins).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Opioid Use Disorder
- Opioid Use Disorder, Severe
- Opioid Use Disorder, Moderate
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Montefiore Medical Center
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Community Health Project Los Angeles (CHPLA) · Los Angeles, CA
District of Columbia · 1
- HIPS · Washington D.C., DC
Louisiana · 1
- CARPBR/Be Safe Syringe Program · Baton Rouge, LA
Minnesota · 1
- Harm Reduction Sisters · Duluth, MN
New Mexico · 1
- Alianza of New Mexico · Roswell, NM
Oregon · 1
- HIV Alliance · Grants Pass, OR
South Carolina · 1
- Challenges, Inc/Prisma Health · Greenville, SC
Wisconsin · 1
- Vivent Health · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.